Schizophrenia Research
Volume 56, Issue 1 , Pages 19-23 , 1 July 2002

d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

  • A.Eden Evins

      Affiliations

    • Harvard Medical School and the Schizophrenia Research Program of the Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-617-912-7832; fax: +1-617-723-3919
    • ,
  • Ed Amico

      Affiliations

    • Harvard Medical School and the Schizophrenia Research Program of the Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
    • ,
  • Thomas A. Posever

      Affiliations

    • Tufts University School of Medicine and the Bay Cove Mental Health Center, Lemuel Shattuck Hospital, Morton Street, Jamaica Plain, MA 02130, USA
    • ,
  • Rob Toker

      Affiliations

    • Tufts University School of Medicine and the Bay Cove Mental Health Center, Lemuel Shattuck Hospital, Morton Street, Jamaica Plain, MA 02130, USA
    • ,
  • Donald C. Goff

      Affiliations

    • Harvard Medical School and the Schizophrenia Research Program of the Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA

Received 28 November 2000 ,Revised 15 March 2001 ,Accepted 19 March 2001.

References 

  1. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 1995;13:177–213
  2. Cascella NG, Macciardi F, Cavallini C, Smeraldi E. d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia. J. Neural. Transm. Gen. Sect. 1994;95:105–111
  3. Corbett R, Camacho R, Woods AT, Kerman LL, Fishkin RJ, Brooks K, et al. Antipsychotic agents antagonize non-competitive NMDA antagonist-induced behaviors. Psychopharmacology. 1995;120:67–74
  4. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev. Psychiatry. 1996;3:241–253
  5. Emmett M, Mick S, Cler J. Actions of d-cycloserine at the N-methyl-d-aspartate-associated glycine receptor site in vivo. Neuropharmacology. 1991;30:1167–1171
  6. Evins AE, Amico ET, Shih V, Goff DC. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J. Neural. Transm. 1997;104:761–766
  7. Evins A, Fitzgerald S, Wine L, Rosselli R, Goff D. A placebo controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry. 2000;157:826–828
  8. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry. 1995;152:1213–1215
  9. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. d-Cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry. 1996;153:1628–1630
  10. Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry. 1999;45:512–514
  11. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry. 1999;56:21–27
  12. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 1999;56:29–36
  13. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 1994;151:1234–1236
  14. Kirkpatrick B, Buchanan R, McKenney P. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119–123
  15. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 1988;241:835–837
  16. Maurel-Remy S, Bervoets K, Millan MJ. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur. J. Pharmacol. 1995;280:R9–R11
  17. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 1995;52:998–1007
  18. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am. J. Psychiatry. 1999;156:145–147
  19. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. d-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 1998;44:1081–1089
  20. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. d-Serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry. 1999;156:1822–1825
  21. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 1990;510:158–160

PII: S0920-9964(01)00220-1

doi: 10.1016/S0920-9964(01)00220-1

Schizophrenia Research
Volume 56, Issue 1 , Pages 19-23 , 1 July 2002

Article Tools